Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma
EGFR and EGFRvIII analysis is of current interest in glioblastoma- the most common malignant primary CNS tumour, because of new EGFRvIII vaccine trials underway. EGFR activation in glioblastoma promotes cellular proliferation via activation of MAPK and PI3K-Akt pathways and EGFRvIII is the most comm...
Main Authors: | Emily ePadfield, Hayley Patricia Ellis, Kathreena M Kurian |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2015-01-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2015.00005/full |
Similar Items
-
GZ17-6.02 Inhibits the Growth of EGFRvIII+ Glioblastoma
by: Justin Choi, et al.
Published: (2022-04-01) -
Simultaneous detection of EGFR amplification and EGFRvIII variant using digital PCR-based method in glioblastoma
by: Maxime Fontanilles, et al.
Published: (2020-04-01) -
Effects of Aptamer to U87-EGFRvIII Cells on the Proliferation, Radiosensitivity, and Radiotherapy of Glioblastoma Cells
by: Xingmei Zhang, et al.
Published: (2018-03-01) -
Increased EGFRvIII Epitope Accessibility after Tyrosine Kinase Inhibitor Treatment of Glioblastoma Cells Creates More Opportunities for Immunotherapy
by: Cezary Tręda, et al.
Published: (2023-02-01) -
Flagellin synergistically enhances anti-tumor effect of EGFRvIII peptide in a glioblastoma-bearing mouse brain tumor model
by: Jin Myung Choi, et al.
Published: (2022-09-01)